From the University of Rochester and Rochester General Hospital, Rochester (E.E.W., A.R.F.), Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.K., D.C., K.R.T., P.R.D., K.U.J., W.C.G.), and New York University Langone Vaccine Center and Grossman School of Medicine, New York (M.J.M., V.R.) — all in New York; Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); the University of...
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 4 papers. Top paper: “Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults”.
Kirsten E. Lyke, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart +20 more
Stephen J. Thomas, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart +26 more
Robert W. Frenck, Ann R. Falsey, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman +23 more
Robert W. Frenck, Ann R. Falsey, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman +20 more